

CERTIFICATION OF ENROLLMENT

SENATE BILL 6234

Chapter 105, Laws of 2024

68th Legislature
2024 Regular Session

BRANCHED-CHAIN KETOACID DEHYDROGENASE KINASE DEFICIENCY—NEWBORN
SCREENING

EFFECTIVE DATE: June 6, 2024

Passed by the Senate February 7, 2024
Yeas 48 Nays 0

DENNY HECK

President of the Senate

Passed by the House February 27, 2024
Yeas 96 Nays 0

Laurie Jinkins

**Speaker of the House of
Representatives**

Approved March 14, 2024 11:44 AM

JAY INSLEE

Governor of the State of Washington

CERTIFICATE

I, Sarah Bannister, Secretary of the Senate of the State of Washington, do hereby certify that the attached is **SENATE BILL 6234** as passed by the Senate and the House of Representatives on the dates hereon set forth.

SARAH BANNISTER

Secretary

FILED

March 14, 2024

**Secretary of State
State of Washington**

SENATE BILL 6234

Passed Legislature - 2024 Regular Session

State of Washington

68th Legislature

2024 Regular Session

By Senators L. Wilson, Hasegawa, and Lovick

Read first time 01/15/24. Referred to Committee on Health & Long Term Care.

1 AN ACT Relating to screening newborn infants for branched-chain
2 ketoacid dehydrogenase kinase deficiency; creating new sections; and
3 providing an expiration date.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

5 NEW SECTION. **Sec. 1.** The legislature finds that there is
6 promising research that individuals with branched-chain ketoacid
7 dehydrogenase kinase deficiency, which is linked to
8 neurodevelopmental disorders including autism spectrum disorder, can
9 potentially benefit significantly from early diagnosis and treatment.
10 The legislature intends to engage the state board of health to
11 conduct an evaluation of whether branched-chain ketoacid
12 dehydrogenase kinase deficiency screening should be added to the
13 newborn screening panel.

14 NEW SECTION. **Sec. 2.** (1) The state board of health shall
15 consider whether or not to add the branched-chain ketoacid
16 dehydrogenase kinase deficiency screening to the mandatory newborn
17 screening panel as required in RCW 70.83.020. The state board of
18 health shall submit to the governor and the appropriate committees of
19 the legislature a report no later than June 30, 2025, that includes a
20 summary of the evaluation conducted in this section and the findings

1 and recommendations on the addition of the branched-chain ketoacid
2 dehydrogenase kinase deficiency screening to the mandatory newborn
3 screening panel.

4 (2) This section expires July 30, 2026.

Passed by the Senate February 7, 2024.

Passed by the House February 27, 2024.

Approved by the Governor March 14, 2024.

Filed in Office of Secretary of State March 14, 2024.

--- END ---